Full Sail Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Full Sail Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$287K	Buy	+510	New	+$288K	0.02%	237

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Full Sail Capital's REGN Position: Q3 2025 in Review

Full Sail Capital opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2025: 510 shares worth $287K. The stake represents 0.02% of the portfolio and ranks #237 among its holdings.

1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Full Sail Capital held 510 shares of Regeneron Pharmaceuticals worth $287K as of Q3 2025.
Regeneron Pharmaceuticals was a new Full Sail Capital position in Q3 2025.
Regeneron Pharmaceuticals made up 0.02% of Full Sail Capital's portfolio in Q3 2025, its #237 holding.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Full Sail Capital's 13F filing for Q3 2025, filed 14 Nov 2025.